ChemicalBook >> CAS DataBase List >>ferric nitrilotriacetate

ferric nitrilotriacetate

CAS No.
16448-54-7
Chemical Name:
ferric nitrilotriacetate
Synonyms
IRONIIINITRILOACETATE;ferric nitrilotriacetate;IRON(III)NITRILOTRIACETATE;FERRICNITRILOTRIACETICACID;FERRICIRONNITRILOTRIACETATE;2-[bis(2-oxido-2-oxoethyl)amino]acetate
CBNumber:
CB61386121
Molecular Formula:
C6H6FeNO6
Molecular Weight:
0
MDL Number:
MOL File:
16448-54-7.mol
MSDS File:
SDS
Last updated:2026-11-04 17:04:05

ferric nitrilotriacetate Properties

Boiling point 82.5°C
form Solid
color Light yellow to yellow
FDA UNII Z3U5ED15B9
Comptox DTXSID DTXSID60167764

SAFETY

Risk and Safety Statements

Hazardous Substances Data 16448-54-7(Hazardous Substances Data)

ferric nitrilotriacetate price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
ChemScene CS-0356846 Ferric nitrilotriacetate 98.0% 16448-54-7 5mg $227 2026-06-04 Buy
ChemScene CS-0356846 Ferric nitrilotriacetate 98.0% 16448-54-7 10mg $379 2026-06-04 Buy
ChemScene CS-0356846 Ferric nitrilotriacetate 98.0% 16448-54-7 25mg $769 2026-06-04 Buy
ChemScene CS-0356846 Ferric nitrilotriacetate 98.0% 16448-54-7 50mg $1246 2026-06-04 Buy
ChemScene CS-0356846 Ferric nitrilotriacetate 98.0% 16448-54-7 100mg $2004 2026-06-04 Buy
Product number Packaging Price Buy
CS-0356846 5mg $227 Buy
CS-0356846 10mg $379 Buy
CS-0356846 25mg $769 Buy
CS-0356846 50mg $1246 Buy
CS-0356846 100mg $2004 Buy

ferric nitrilotriacetate Chemical Properties, Uses, Production

Uses

Ferric nitrilotriacetate (Fe-NTA), a complexation of nitriloacetic acid with iron, is a highly reactive compound used to induce degenerative disorders through oxidative stress (OS). Ferric nitrilotriacetate is also used in several studies to induce hyperglycemia, glycosuria, and both renal and liver carcinogenesis[1].

in vivo

Ferric nitrilotriacetate can be used in animal modeling to create renal tumor and diabetes models. After intraperitoneal injection into mice, it deposits heavily in the liver and pancreas[1][2][3][4].

Induction of renal tumors[3]
Background
Ferric nitrilotriacetate can induce oxidative stress, leading to lipid peroxidation of renal cell membranes and DNA damage, thereby promoting the development of renal tumors[1][2].
Specific Modeling Methods
Mice: A/J male 4-week-old
Administration: 1.8-2.7 mg of Fe/kg ip once daily, 6 days a week for 12 weeks
Note
1.8 to 2.7 mg refers to the amount of Fe contained in ferric nitrilotriacetate.
Modeling Indicators
Pathological Changes: The renal proximal tubular (PCT) cells in mice exhibit degeneration, necrosis, and shedding. Many PCT cells show regenerative characteristics, with some regenerative cells being abnormally large and featuring prominent nucleoli and mitoses. Some regenerative cells lack tubular formation.
Phenotypic Observations: Renal tubular cell tumors develop. The appearance of renal tumors includes solid, cystic, or hemorrhagic forms. Microscopic examination reveals tumor cells with clear, granular, or spindle shapes, forming solid aggregates, papillae, cysts, or glandular patterns.
Correlated Product(s): /
Opposite Product(s): /

Induction of diabetes[4]
Background
Ferric nitrilotriacetate causes significant iron deposition in the pancreas, leading to oxidative stress through the generation of reactive oxygen species (ROS) and free radicals. This results in damage and functional failure of pancreatic islet β-cells, reducing insulin secretion and consequently inducing diabetes.[4].
Specific Modeling Methods
Rat: Wistar male and female
Administration: 200 mg/rat ip once daily, Specifics of the administration method are detailed in the note
Note
Rats received intraperitoneal injections of Ferric nitrilotriacetate, with each rat receiving a total of approximately 200 mg of iron. The dosage and frequency of administration were as follows:
Weeks 1-3: 2 mg Fe/kg, once daily;
Weeks 3-6: 6 mg Fe/kg, once daily;
Next 2 months: 10 mg Fe/kg, once daily.
Modeling Indicators
Pathological Changes: Significant iron deposition was observed in the exocrine cells of the pancreas in mice, with a reduction in insulin-storing β granules in the islet β cells and a decrease in zinc ion content.
Phenotypic Observations: Mice exhibited diabetic symptoms, including hyperglycemia, glycosuria, ketonemia, and ketonuria.
Correlated Product(s): /
Opposite Product(s): /

References

[1] Jol Essogo J, et al. Zanthoxylum heitzii Modulates Ferric Nitrilotriacetate-Dependent Oxidative Alterations in Four Vital Organs: An In Vitro Organoprotective Model. Evid Based Complement Alternat Med. 2017;2017:6058150. DOI:10.1155/2017/6058150
[2] Inoue S, et al. Hydroxyl radical production and human DNA damage induced by ferric nitrilotriacetate and hydrogen peroxide. Cancer Res. 1987 Dec 15;47(24 Pt 1):6522-7. PMID:2824034
[3] Li JL, et al. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res. 1987 Apr 1;47(7):1867-9. PMID:3815378
[4] Awai M, et al. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am J Pathol. 1979 Jun;95(3):663-73. PMID: 377994; PMID:377994

ferric nitrilotriacetate Preparation Products And Raw materials

Raw materials

Preparation Products

ferric nitrilotriacetate Suppliers

Global Suppliers ( 4)
Supplier Tel Email Country ProdList Advantage
Tianjin Kailiqi Biotechnology Co., Ltd. 15076683720 klq@cw-bio.com China 9776 55
TargetMol Chemicals Inc. 15002134094 marketing@targetmol.cn China 29874 58
Henan Tianfu Chemical Co.,Ltd. +86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21531 55
TargetMol Chemicals Inc. 13564774135 marketing@targetmol.com United States 19950 58

View Latest Price from ferric nitrilotriacetate manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Ferric nitrilotriacetate pictures 2026-07-15 Ferric nitrilotriacetate
16448-54-7
10g TargetMol Chemicals Inc.
ferric nitrilotriacetate FERRICNITRILOTRIACETICACID IRONIIINITRILOACETATE IRON(III)NITRILOTRIACETATE FERRICIRONNITRILOTRIACETATE 2-[bis(2-oxido-2-oxoethyl)amino]acetate 16448-54-7